Posted by Michael Wonder on 23 Oct 2020
TLV reconsiders the subsidy of Rinvoq
23 October 2020 - TLV starts a reconsideration of the current subsidy status for Rinvoq.
The background to the reconsideration is that the regions have submitted to TLV with an application for a price change and requested a tripartite consultation for the drug Rinvoq.
This has resulted in a side agreement between the regions and the company that markets Rinvoq. In the light of the established side agreement, TLV has started this reconsideration to investigate whether the current subsidy status should be changed.
